Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Genmab A/S - American Depositary Shares
(NQ:
GMAB
)
33.69
+0.59 (+1.77%)
Streaming Delayed Price
Updated: 1:50 PM EST, Jan 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Genmab A/S - American Depositary Shares
Benzinga's Top Ratings Upgrades, Downgrades For August 24, 2023
↗
August 24, 2023
Via
Benzinga
Analyst Expectations for Genmab's Future
↗
August 15, 2023
Via
Benzinga
Is AbbVie Still a Good Dividend Stock to Buy?
↗
August 08, 2023
Find out if AbbVie can overcome sinking sales of its top-selling product.
Via
The Motley Fool
3 Things About Johnson & Johnson Every Smart Investor Knows
↗
July 28, 2023
The company has been a strong value stock but faces big changes this year.
Via
The Motley Fool
12 Analysts Have This to Say About Genmab
↗
July 24, 2023
Via
Benzinga
Where Genmab Stands With Analysts
↗
June 26, 2023
Via
Benzinga
Expert Ratings for Genmab
↗
June 06, 2023
Via
Benzinga
Recap: Genmab Q1 Earnings
↗
May 10, 2023
Via
Benzinga
3 Biotech Stocks You Better Be Buying on Each and Every Dip
↗
July 27, 2023
Biotech companies can bring about life-changing innovations. We've created a list to help you find the best biotech stocks out there.
Via
InvestorPlace
Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
July 21, 2023
From
Genmab A/S
Via
Business Wire
3 Biotech Stocks That AI is Loving in July
↗
July 12, 2023
As AI becomes a more entrenched aspect of society, investors can lean on these AI recommended biotech stocks with predicted high potential.
Via
InvestorPlace
Could This New Drug Be a Blockbuster for These 2 Pharma Collaborators?
↗
July 02, 2023
In May, the FDA approved epcoritamab, developed by AbbVie and Genmab, as a treatment for a type of blood cancer.
Via
The Motley Fool
How To Attend Genmab Q1 2023 Earnings Conference Call
↗
May 08, 2023
Via
Benzinga
Price Over Earnings Overview: Genmab
↗
April 27, 2023
Via
Benzinga
Analyst Ratings for Genmab
↗
April 20, 2023
Via
Benzinga
P/E Ratio Insights for Genmab
↗
April 11, 2023
Via
Benzinga
This Foreboding Sign Looms Over Genmab's Chart
↗
March 31, 2023
Via
Benzinga
Genmab/AbbVie's Blood Cancer Treatment Shows 82% Response Rate In Pretreated Follicular Lymphoma Patients
↗
June 28, 2023
Genmab A/S (NASDAQ: GMAB) and AbbVie Inc (NYSE: ABBV) have announced topline results from the follicular lymphoma (FL) cohort of the phase 1/2 EPCORE NHL-1 clinical trial evaluating epcoritamab...
Via
Benzinga
Genmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
June 27, 2023
From
Genmab
Via
Business Wire
Genmab Announces Epcoritamab Added to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for ‘B-Cell Lymphomas’
June 22, 2023
From
Genmab
Via
Business Wire
What 4 Analyst Ratings Have To Say About Genmab
↗
March 01, 2023
Via
Benzinga
Earnings Outlook For Genmab
↗
February 21, 2023
Via
Benzinga
Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas at European Hematology Association (EHA) Annual Meeting 2023
June 09, 2023
From
Genmab
Via
Business Wire
Genmab Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress
May 25, 2023
From
Genmab A/S
Via
Business Wire
FDA Approves AbbVie/Genmab's Cancer Drug As First Bispecific Antibody For Type Of Lymphoma In Adult Patients
↗
May 19, 2023
The FDA has approved Epkinly (epcoritamab-bysp) as the first and only T-cell engaging bispecific antibody for adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)...
Via
Benzinga
EPKINLY™ (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
May 19, 2023
From
Genmab A/S
Via
Business Wire
Focus On Genmab's Pipeline If Darzalex Arbitration with Janssen Goes Sideways: Analyst
↗
April 24, 2023
Via
Benzinga
Genmab Stock Hits 80-Plus Relative Strength Rating Benchmark
↗
April 17, 2023
On Monday, Genmab stock saw its Relative Strength (RS) Rating jump into the 80-plus percentile, rising to 84, up from 80 the day before.
Via
Investor's Business Daily
Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
April 17, 2023
From
Genmab
Via
Business Wire
Alkermes Stock Sees Rising Relative Price Strength
↗
February 17, 2023
The Relative Strength (RS) Rating for Alkermes stock entered a new percentile Friday, with an increase from 79 to 86.
Via
Investor's Business Daily
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
